Cambridge Investment Research Advisors
SPRO icon

Cambridge Investment Research Advisors’s Spero Therapeutics SPRO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,423
Closed -$667K – 2980
2020
Q4 		$667K Buy
+34,423
New +$537K ﹤0.01% 1575

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Cambridge Investment Research Advisors's SPRO Position: Q1 2021 in Review

Cambridge Investment Research Advisors sold out of Spero Therapeutics (SPRO) in Q1 2021, closing a stake of 34,423 shares — an estimated $667K sold.

Cambridge Investment Research Advisors first reported a position in SPRO in Q4 2020 and held it in 1 quarter. The position peaked at $667K in Q4 2020. 94 funds tracked by Wall St. Rank hold SPRO as of Q1 2021.

  • Cambridge Investment Research Advisors reported no remaining Spero Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 34,423 Spero Therapeutics shares in Q1 2021, an estimated $667K.
  • Cambridge Investment Research Advisors first reported a position in Spero Therapeutics in Q4 2020 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Spero Therapeutics position peaked at $667K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2021, filed 7 May 2021.